SCHEMBL10167028

SCHEMBL10167028

CS(=O)(=O)N1CCc2cc(S(=O)(=O)c3ccccc3)ccc21

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.67
POLB P06746 4/20 0.61
GLA P06280 1/20 0.61
TP53 P04637 1/20 0.56
MAPT P10636 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.54
HPGD P15428 1/20 0.52
DRD3 P35462 3/20 0.51
HTR6 P50406 3/20 0.51
CYP11B1 P15538 1/20 0.51
CYP11B2 P19099 1/20 0.51
NPC1 O15118 3/20 0.51
RAB9A P51151 3/20 0.51
TSHR P16473 1/20 0.51
MMP13 P45452 1/20 0.51
LMNA P02545 1/20 0.50
HTT P42858 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
HRH3 Q9Y5N1 2/20 0.49
HTR2C P28335 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2693394 0.85 PKM (0.62) PKMPOLBGLATP53MAPT
SCHEMBL2693176 0.81 THRB (0.62) PKMPOLBGLATP53MAPT
SCHEMBL4710261 0.81 POLB (0.66) PKMPOLBGLATP53MAPT
SCHEMBL2694519 0.80 PKM (1.00) PKMPOLBGLATP53MAPT
SCHEMBL2102471 0.76 KMT2A (0.58) PKMPOLBGLAMAPTL3MBTL1
SCHEMBL28308392 0.76 POLB (0.56) PKMPOLBGLATP53MAPT
SCHEMBL5024162 0.75 POLB (0.58) PKMPOLBGLAL3MBTL1HPGD
SCHEMBL13989656 0.75 HTR6 (0.50) PKMDRD3HTR6LMNAHTT
SCHEMBL2692236 0.75 MEN1 (0.74) PKMMAPTDRD3HTR6NPC1
SCHEMBL852214 0.74 POLB (0.57) PKMPOLBGLAL3MBTL1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8692001-B2 Sulfonamides for the modulation of PKM2 DYNAMIX PHARMACEUTICALS LTD. (IL) 2014-04-08 US disclosed
US-8692001-B2 Sulfonamides for the modulation of PKM2 DYNAMIX PHARMACEUTICALS LTD. (IL) 2014-04-08 US disclosed
WO-2012056319-A1 SULFONAMIDES FOR THE MODULATION OF PKM2 DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-05-03 WO disclosed
US-20120108631-A1 Sulfonamides for the Modulation of PKM2 DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-05-03 US disclosed
US-20120108631-A1 Sulfonamides for the Modulation of PKM2 DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108631-A1 Sulfonamides for the Modulation of PKM2 PDK1, PDK4, PDK2 PKM 5/4885POLB 4129/4885GLA 3136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.